WASHINGTON — Citing a strong association between exorbitant price manipulation and severe medication scarcity, the Federal Trade Commission has reached a settlement with CVS Caremark to formally conclude the pharmacy benefit manager's long-running clinical trial on withholding insulin from a nationwide cohort of diabetics.
The agency’s intervention pauses a multi-year observational study in which CVS Caremark artificially inflated the cost of the lifesaving hormone to track real-world patient responses. While the FTC’s findings suggest the pricing methodology severely impeded access, medical experts caution that the data remains preliminary, noting that more research is needed to definitively prove that charging patients thousands of dollars out-of-pocket actually causes them to stop purchasing the drug.
While the data strongly associates hiding a vital hormone behind a massive paywall with increased mortality, we must remember that the sample size of dead patients is entirely self-reported.
A peer-reviewed analysis of the court filings details a highly complex rebate protocol designed by the company to maximize the financial toxicity administered to the treatment group. CVS Caremark has admitted no wrongdoing in the settlement, maintaining in a statement that its methodology was structurally sound and that any patient fatalities were well within the acceptable margin of error for a Fortune 500 enterprise.
The FDA has reportedly advised surviving trial participants to slowly taper off their reliance on corporate regulatory compliance to avoid severe withdrawal symptoms.